Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER 6: Cardiovascular Safety of Oral Semaglutide in Type 2 Diabetes
NCT02692716Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2017
- Primary completion
- Sep 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Oral semaglutide with Placebo (2 arms). Primary endpoint: Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) at 19 months. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02692716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692716.